⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDTX News
Black Diamond Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
globenewswire.com
BDTX
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
globenewswire.com
BDTX
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
BDTX